ASX News
Activities Report and Appendix 4C for September 2021 Quarter
Melbourne (Australia) – 21 October 2021. Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 September 2021.
Telix today provides its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 September 2021.
Telix CEO Dr. Christian Behrenbruch stated, “Telix has been intensely focused on preparations for the launch of the Company’s first commercial product Illuccix® (TLX591-CDx), while at the same time continuing to effectively advance the programs in its multi-asset core clinical pipeline. The clinical activity underway in 2021 will underpin our transition to a globally-active therapeutic radiopharmaceutical company, and the team continues to work tirelessly towards the goal of bringing additional products to market to unlock the value in our research portfolio.”
To view the full Appendix 4C and Activities Report please click here.
To return to Telix’s homepage please click here.
More Articles
ASX News
Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil
Melbourne (Australia) and Porto Alegre (Brazil) – 1 December 2021. The Brazilian Health Regulatory Agency has granted an exceptional authorisation...
Corporate Spotlight
First Telix and Duchembio Joint Symposium – Emergence of PSMA-PET Imaging in South Korea
22 November 2021 – Clinical Spotlight | Telix and Duchembio announce a joint symposium on 68Ga-PSMA-PET imaging in Korea
Corporate Spotlight
NOBLE Study Brings Advanced Prostate Imaging to Rural Australia – First Patient Dosed
Melbourne (Australia) – 15 November 2021. The first Australian patient has been dosed in the international NOBLE Registry, a study aimed at improving access to state-of-the-art prostate...
Corporate Spotlight
ZIRCON Presentation at International Kidney Cancer Symposium 2021
8 November 2021 – Corporate Spotlight | Telix presents Phase III ZIRCON trial at the International Kidney Cancer Symposium 2021
ASX News
Australian TGA Approves Illuccix® for Prostate Cancer Imaging
Melbourne (Australia) – 02 November 2021. Australian Therapeutic Goods Administration has approved Illuccix® for the diagnostic imaging of men with prostate...
Corporate Spotlight
Telix Japan – Upcoming Events in November
22 October 2021 | Corporate Spotlight | Telix Japan Upcoming Events in November
ASX News
Activities Report and Appendix 4C for September 2021 Quarter
Melbourne (Australia) – 21 October 2021. Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 September 2021.
ASX News
IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting
Melbourne (Australia) and Indianapolis (U.S.A.) – 20 October 2021. Telix presented the IPAX-1 study of TLX101 in glioblastoma at the...
Corporate Spotlight
Telix Satellite Symposium at European Association of Nuclear Medicine Annual Congress 2021
15 October 2021 – Clinical Spotlight | Telix Satellite Symposium at the European Association of Nuclear Medicine 2021 Virtual Conference.
Corporate Spotlight
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
Potential Indication Expansion for Telix’s Core Kidney Cancer Theranostic Program Melbourne (Australia) and Liège (Belgium) – 5 October 2021. Telix announces...
Corporate Spotlight
Telix Establishes Commercial Hub in Geneva, Switzerland
Melbourne (Australia) and Geneva (Switzerland) – 4 October 2021. Telix announces that it has established a new commercial hub in...
Corporate Spotlight
Second Industry Body Updates Guidance for Use of PSMA PET Imaging
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 21 September 2021. Telix welcomes SNMMI updated Appropriate Use Criteria for PSMA PET...
Corporate Spotlight
Telix at AdMeTech Summit on Precision Diagnosis and Treatment of Prostate Cancer
16 September 2021 – Clinical Spotlight | Telix to support and participate in AdMeTech 5th Global Summit on Precision Diagnosis...
ASX News
NCCN Guidelines Updated to Include PSMA-PET Imaging
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 14 September 2021. Telix welcomes the updated NCCN Guidelines® for prostate cancer, which includes...
ASX News
FDA Approves Phase II Kidney Cancer Therapy Study
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 14 September 2021. Telix announces the FDA has accepted the IND Application to...
ASX News
Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging
Melbourne (Australia) and Bologna (Italy) – 13 September 2021. Telix enters a commercial distribution agreement with Radius for Telix’s prostate...
ASX News
Japanese Prostate Cancer Imaging Study Completes Enrolment
Melbourne (Australia) and Kyoto (Japan) – 9 September 2021. Telix has completed a Phase I clinical trial of TLX591-CDx for...
ASX News
Telix to Collaborate with Kettering Health on Diagnostic PSMA Imaging & Targeting Theranostics
Melbourne (Australia), Indianapolis (IN, U.S.A.), and Kettering (OH, U.S.A.) – 7 September 2021. Telix announces collaboration with Kettering Health on...
ASX News
Telix and Lightpoint Medical to Collaborate on Radioguided Surgery
Melbourne (Australia) – 23 August 2021. Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI®...
ASX News
Telix Half-Year Results 2021 and Company Update Conference Call
Melbourne (Australia) – 19 August 2021. Telix announces Half-Year Results 2021 and provides shareholder update
ASX News
Telix Expands Prostate Cancer Activity with GenesisCare Collaboration
Melbourne (Australia) – 19 August 2021. Telix releases details of two ancillary studies under the ProstACT program, including a Phase...
ASX News
Telix and Merck to Commence Pan-Cancer Clinical Combination Studies
Melbourne (Australia) – 18 August 2021. Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany.
ASX News
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
Melbourne (Australia) – 18 August 2021. Telix announces two new studies to evaluate the potential utility of TLX591-CDx and TLX250-CDx...
ASX News
Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®
Melbourne and Adelaide (Australia) – 17 August 2021. Telix extends partnership with AusHealth relating to APOMAB®, a novel theranostic being...
ASX News
Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia
Melbourne (Australia) and London (United Kingdom) – 17 August 2021. Telix announces Phase II academic study of TLX66 in children...
ASX News
Telix H1 2021 Results and Company Update Conference Call
Melbourne (Australia) – 11 August 2021. Telix to hold investor conference call to present H1 2021 financial results and Company...
ASX News
First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer
Melbourne (Australia) – 5 August 2021. Telix announces the first patient has been dosed in its ‘CUPID’ Phase I study...
Corporate Spotlight
Ms. Helen Hovenga Joins Telix as Chief People Officer
4 August 2021 – Corporate Spotlight | Telix announces the appointment of Ms. Helen Hovenga in the role of Chief...
ASX News
Telix Seneffe Production Facility: Progress Update
Melbourne (Australia) and Seneffe (Belgium) – 30 July 2021. Telix authorised to decommission first of two cyclotrons at Seneffe radiopharmaceutical...
ASX News
Activities Report and Appendix 4C for June 2021 Quarter
Melbourne (Australia) – 22 July 2021. Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 June...
ASX News
ZIRCON Phase 3 Renal Cancer Imaging Study: Progress Update
Melbourne (Australia) – 20 July 2021. Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer...
Corporate Spotlight
Telix Appoints Gabrielle Wermenbol as Chief Financial Officer, EMEA
19 July 2021 – Corporate Spotlight | Gabrielle Wermenbol joins Telix as Chief Financial Officer, Europe, Middle East & Africa...
Corporate Spotlight
Kyahn Williamson Joins Telix to Lead Corporate Communications and Investor Relations
Melbourne (Australia) – 12 July 2021. Telix announces that Ms. Kyahn Williamson has joined the Telix executive leadership team in...
ASX News
First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
Melbourne (Australia) – 23 June 2021. Telix announces that a first patient has been dosed in a Phase I study...
ASX News
IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update
Melbourne (Australia) – 21 June 2021. Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on...
ASX News
Telix Update on FDA New Drug Application Review for Illuccix®
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 17 June 2021. Telix announces participation in a late-cycle meeting with the U.S....
Corporate Spotlight
Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research
MELBOURNE, Australia and INDIANAPOLIS 14 June, 2021 – Telix announces the launch of a new educational platform focused on radiopharmaceutical...
Corporate Spotlight
Telix launches “Gallium Wave” Awareness Website
Melbourne (Australia) and Indianapolis (U.S.A.) – 11 June 2021. Telix announces the launch of a new website “Gallium Wave”, as...
Corporate Spotlight
Scott Law joins Telix as SVP Global Manufacturing Operations
11 June 2021 – Corporate Spotlight | Scott Law joins Telix as Senior Vice President Global Manufacturing Operations
ASX News
Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy
Liège (Belgium) and Gothenburg (Sweden) – 7 June 2021. Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of...